Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS1 | P29475 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | MAOB | P27338 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.51 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 5/20 | 0.50 |
| ▸ | MEN1 | O00255 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | METAP2 | P50579 | 1/20 | 0.50 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | CLK1 | P49759 | 2/20 | 0.46 |
| ▸ | CLK2 | P49760 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29509879 | 1.00 | NOS1 (0.55) | NOS1MAPTPOLBMAOBMAPK1 | |
| SCHEMBL1076913 | 0.86 | MEN1 (0.55) | NOS1MAPTMAPK1MEN1KMT2A | |
| SCHEMBL31647068 | 0.82 | KDR (0.57) | NOS1MAPTPOLBMAOBMAPK1 | |
| SCHEMBL10179696 | 0.82 | TMEM97 (0.52) | NOS1MAPTPOLBMAOBMAPK1 | |
| SCHEMBL3058692 | 0.82 | MAPK1 (0.55) | NOS1MAPTPOLBMAOBMAPK1 | |
| SCHEMBL6298004 | 0.82 | NOS1 (0.51) | NOS1MAPTPOLBMAOBMAPK1 | |
| SCHEMBL5220947 | 0.82 | KDR (0.57) | NOS1MAPTPOLBMAOBMAPK1 | |
| Hydrochloric Acid SCHEMBL27659736 | 0.81 | MAPK1 (0.54) | NOS1MAPTPOLBMAOBMAPK1 | |
| SCHEMBL19639914 | 0.78 | ROCK2 (0.50) | NOS1MAPTPOLBMAOBMAPK1 | |
| SCHEMBL28999287 | 0.78 | ROCK2 (0.51) | NOS1MAPTPOLBMAOBMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, INC. | 2024-02-01 | — | — | US | disclosed |
| CN-116744918-A | HSD17B13 inhibitors and uses thereof | FL2022-001公司 | 2023-09-12 | — | — | CN | disclosed |
| EP-4221702-A1 | HSD17B13 INHIBITORS AND USES THEREOF | FL2022-001, Inc. (US) | 2023-08-09 | — | — | EP | disclosed |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2023-01-24 | — | — | US | disclosed |
| EP-3464292-B1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARM INC (US) | 2022-09-21 | — | — | EP | disclosed |
| CN-109563103-B | Modulators of beta-3 adrenergic receptors for the treatment or prevention of disorders related thereto | 艾尼纳制药公司 | 2022-05-27 | — | — | CN | disclosed |
| WO-2022072512-A1 | HSD17B13 INHIBITORS AND USES THEREOF | METACRINE, INC. (US) | 2022-04-07 | — | — | WO | disclosed |
| US-20210340154-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ARENA PHARMACEUTICALS, INC. | 2021-11-04 | — | — | US | disclosed |
| US-10927123-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ARENA PHARMACEUTICALS, INC. (US) | 2021-02-23 | — | — | US | disclosed |
| US-10889555-B2 | Sulfonamide compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2021-01-12 | — | — | US | disclosed |
| CN-100369899-C | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2008-02-20 | — | — | CN | disclosed |
| CN-1997363-A | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2007-07-11 | — | — | CN | disclosed |
| EP-1750696-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2007-02-14 | — | — | EP | disclosed |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2006-11-16 | — | — | US | disclosed |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SEQUOIA PHARMACEUTICALS (US) | 2005-12-01 | — | — | US | disclosed |
| WO-2005110428-A2 | RESISTANCE-REPELLENT RETROVIRAL PROTEASE INHIBITORS | SEQUOIA PHARMACEUTICALS, INC. (US) | 2005-11-24 | — | — | WO | disclosed |
| CN-1642922-A | Substituted indazoles with anti-cancer activity | AVENTIS PHARMA SA (FR) | 2005-07-20 | — | — | CN | disclosed |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-03-17 | — | — | US | disclosed |
| US-6858638-B2 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2005-02-22 | — | — | US | disclosed |
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | AVENTIS PHARMA S.A. (FR) | 2004-06-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040106667-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NOS1 1083/4885MAPT 2426/4885POLB 1912/4885 |
| US-20050267074-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | NOS1 3891/4885MAPT 1132/4885POLB 697/4885 |
| US-20210340154-A1 | MODULATORS OF THE BETA-3 ADRENERGIC RECEPTOR USEFUL FOR THE TREATMENT OR PREVENTION OF DISORDERS RELATED THERETO | ADRB3, ADRB1, ADRB2 | NOS1 1317/4885MAPT 4585/4885POLB 2974/4885 |
| US-20060258627-A1 | Resistance-repellent retroviral protease inhibitors | SERPINB1, MMP7, MME | NOS1 3891/4885MAPT 1132/4885POLB 697/4885 |
| US-10889555-B2 | Sulfonamide compound or salt thereof | RNASEH1, SNRPA1, RRM2 | NOS1 809/4885MAPT 4312/4885POLB 930/4885 |
| US-20240034736-A1 | HSD17B13 INHIBITORS AND USES THEREOF | HSD17B3, HSD17B11, HSD17B1 | NOS1 2537/4885MAPT 2694/4885POLB 265/4885 |
| US-20050059722-A1 | Substituted indazoles, compositions containing them, method of production and use | ABL1, CDK3, CILK1 | NOS1 1361/4885MAPT 3070/4885POLB 1915/4885 |
| US-10927123-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | NOS1 1360/4885MAPT 4632/4885POLB 2990/4885 |
| US-11560386-B2 | Modulators of the beta-3 adrenergic receptor useful for the treatment or prevention of disorders related thereto | ADRB3, ADRB1, ADRB2 | NOS1 1360/4885MAPT 4632/4885POLB 2990/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.